Literature DB >> 11967642

Low dose sodium valproate in the treatment of juvenile myoclonic epilepsy.

Anna Karlovassitou-Koniari1, Dimitra Alexiou, Petros Angelopoulos, Pantelis Armentsoudis, Evangelia Dimitrakoudi, Ioannis Delithanasis, Paris Hamlatzis, Stavros Baloyannis.   

Abstract

Fourteen patients with juvenile myoclonic epilepsy (JME) were treated with a single low dose of a sustained-release preparation of sodium valproate (VPA, 500 mg daily). The mean age of the onset of the low dose treatment was 19.2 years (range 14-26). Before this treatment, six patients had been treated with high dose VPA for a period of more than 2 years, three patients for 1 to 2 years, three patients less than 1 year and two patients initiated the treatment from the beginning with a low dose. The mean duration of low dose treatment is 35.6 months (range 25-59 months). (All patients are still under medication). Generalized tonic-clonic and absence seizures were controlled in all patients. Myoclonic jerks relapsed only in one patient, a young mother who was looking after her newly born baby and was deprived of sleep. No adverse reactions have been reported. We suggest that JME patients can effectively be treated with single low VPA dose (500 mg daily), while at the same time seizure precipitating factors, such as sleep deprivation and alcohol ingestion, should be avoided.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11967642     DOI: 10.1007/s004150200028

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  5 in total

1.  High-dose versus low-dose valproate for the treatment of juvenile myoclonic epilepsy: Going from low to high.

Authors:  Laura E Hernández-Vanegas; Aurelio Jara-Prado; Adriana Ochoa; Nayelli Rodríguez Y Rodríguez; Reyna M Durón; Daniel Crail-Meléndez; Ma Elisa Alonso; Antonio V Delgado-Escueta; Iris E Martínez-Juárez
Journal:  Epilepsy Behav       Date:  2016-06-11       Impact factor: 2.937

Review 2.  Juvenile myoclonic epilepsy: epidemiology, pathophysiology, and management.

Authors:  Timothy E Welty
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

3.  Idiopathic Generalized Epilepsy.

Authors:  Joseph E. Sullivan; Dennis J. Dlugos
Journal:  Curr Treat Options Neurol       Date:  2004-05       Impact factor: 3.598

4.  Treatment of myoclonic seizures in patients with juvenile myoclonic epilepsy.

Authors:  Stéphane Auvin
Journal:  Neuropsychiatr Dis Treat       Date:  2007-12       Impact factor: 2.570

5.  Factors Associated with Good Seizure Control in Patients on Valproic Acid.

Authors:  Mastura Ahmad; Ab Fatah Ab Rahman; Sapiah Sapuan
Journal:  Eurasian J Med       Date:  2020-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.